Logo do repositório
 
Publicação

Validation of next-generation sequencing for the diagnosis of hereditary breast and ovarian cancer

2015-11-05Documento de conferência Acesso aberto
Ver registo simples
dc.contributor.authorTheisen, Patrícia
dc.contributor.authorSilva, Catarina
dc.contributor.authorPereira-Caetano, Iris
dc.contributor.authorRodrigues, Pedro
dc.contributor.authorIsidro, Glória
dc.contributor.authorVieira, Luís
dc.contributor.authorGonçalves, João
dc.date.accessioned2016-02-02T14:27:28Z
dc.date.available2016-02-02T14:27:28Z
dc.date.issued2015-11-05
dc.description.abstractIntroduction: Molecular diagnosis of hereditary breast and ovarian cancer (HBOC) has been mostly based on the identification of germline inactivating mutations in the high-penetrant genes BRCA1 and BRCA2. Although several other HBOC susceptibility genes have been identified, mutations in any of those are rare, rendering sequential genetic testing with standard methodologies time consuming and expensive. Next-generation sequencing (NGS) gene panels allow the simultaneous sequencing of multiple HBOC susceptibility genes at a lower cost. The aim of this work was to validate the use of an NGS cancer susceptibility gene panel for the identification of mutations previously detected by Sanger sequencing in the BRCA1, BRCA2 and TP53 genes. Methods: 20 samples from patients with personal/family history of breast cancer were sequenced on a MiSeq using the Trusight Cancer Sequencing Panel (Illumina). Bioinformatic analysis of NGS data included the MiSeq Reporter, VariantStudio and Isaac Enrichment tools (Illumina). Results: NGS successfully identified all 204 variants (38 unique, including 2 deletions and a splice variant) previously detected by Sanger sequencing in the BRCA1, BRCA2 and TP53 genes. Until now, no false-negative or false-positive results were obtained. Discussion: These results demonstrate the high analytical sensitivity and specificity obtained with NGS for the detection of sequence variants in 3 HBOC high-penetrant genes. These validation assays open the way to the definition of a clinically useful multigene panel for HBOC susceptibility based on the Trusight Cancer Sequencing Panel. This will allow a comprehensive and cost-effective molecular diagnosis of HBOC with a shorter turnaround time when compared to standard methodologies. In addition, with appropriate genetic counselling and specialized clinical surveillance, families with HBOC will benefit from these new technologies which have high impact in public health.pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.18/3260
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.subjectDoenças Genéticaspt_PT
dc.subjectCancro da Mamapt_PT
dc.subjectNGSpt_PT
dc.subjectSequenciação de Nova Geraçãopt_PT
dc.subjectBreast Cancerpt_PT
dc.subjectOvarian Cancerpt_PT
dc.titleValidation of next-generation sequencing for the diagnosis of hereditary breast and ovarian cancerpt_PT
dc.typeconference object
dspace.entity.typePublication
oaire.citation.conferencePlacePorto, Portugalpt_PT
oaire.citation.title19.ª Reunião Anual da Sociedade Portuguesa de Genética Humana, 5-7 de Novembro 2015pt_PT
rcaap.rightsopenAccesspt_PT
rcaap.typeconferenceObjectpt_PT

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
Resumo SPGH 2015_Cancro mama hereditário e NGS_Final.pdf
Tamanho:
9.12 KB
Formato:
Adobe Portable Document Format
Ver/Abrir
Licença
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
license.txt
Tamanho:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Ver/Abrir

Coleções

DGH - Apresentações orais em encontros nacionais